Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Holoclar for limbal stem cell deficiency due to ocular burns
2014-002845-23Phase 4Completed
- Sponsor
- Holostem
- Start
- Jul 2015
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ex vivo reconstructed autologous human corneal epithelium containing stem cells in limbal stem cell deficiency (LSCD) and corneal ulcer, sponsored by Holostem. Primary endpoint: Percentage of patients with transplantation success. Started Jul 2015; status: completed.
02
Drugs
ex vivo reconstructed autologous human corneal epithelium containing stem cells
03
Conditions
limbal stem cell deficiency (LSCD)corneal ulcer
Beyond the preview
Go deeper on 2014-002845-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002845-23.